This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2005 Nov 23;294(20):2630-2.

doi: 10.1001/jama.294.20.2630.

Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme

David A Henry¹, Suzanne R Hill, Anthony Harris

Affiliations

PMID: 16304078
DOI: 10.1001/jama.294.20.2630

Comparative Study

Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme

David A Henry et al. JAMA. 2005.

. 2005 Nov 23;294(20):2630-2.

doi: 10.1001/jama.294.20.2630.

Authors

David A Henry¹, Suzanne R Hill, Anthony Harris

Affiliation

¹ School of Medicine and Public Health, University of Newcastle, New South Wales, Australia. david.henry@newcastle.edu.au

PMID: 16304078
DOI: 10.1001/jama.294.20.2630

No abstract available

PubMed Disclaimer

Comment in

Cost-effectiveness and resource allocation.
Cohen JP. Cohen JP. JAMA. 2006 Jun 21;295(23):2723; author reply 2723-4. doi: 10.1001/jama.295.23.2723-a. JAMA. 2006. PMID: 16788126 No abstract available.

Comment on

Quality, innovation, and value for money: NICE and the British National Health Service.
Pearson SD, Rawlins MD. Pearson SD, et al. JAMA. 2005 Nov 23;294(20):2618-22. doi: 10.1001/jama.294.20.2618. JAMA. 2005. PMID: 16304076

Similar articles

NICE and new: appraising innovation.
Ferner RE, Hughes DA, Aronson JK. Ferner RE, et al. BMJ. 2010 Jan 5;340:b5493. doi: 10.1136/bmj.b5493. BMJ. 2010. PMID: 20051468 No abstract available.
Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
Lopert R. Lopert R. Issue Brief (Commonw Fund). 2009 Jul;60:1-13. Issue Brief (Commonw Fund). 2009. PMID: 19639714
Economic evaluation for pharmaceuticals in Germany.
Jönsson B. Jönsson B. Eur J Health Econ. 2007 Sep;8 Suppl 1:S1-2. doi: 10.1007/s10198-007-0066-1. Eur J Health Econ. 2007. PMID: 17638033 No abstract available.
[Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
Castillo-Laborde C, Silva-Illanes N. Castillo-Laborde C, et al. Rev Med Chil. 2014 Jan;142 Suppl 1:S33-8. doi: 10.4067/S0034-98872014001300006. Rev Med Chil. 2014. PMID: 24861178 Review. Spanish.
Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J, Vauth C, Mittendorf T, Greiner W. von der Schulenburg J, et al. Eur J Health Econ. 2007 Sep;8 Suppl 1:S5-31. doi: 10.1007/s10198-007-0063-4. Eur J Health Econ. 2007. PMID: 17582539 Review.

See all similar articles

Cited by

Economic evaluation of an extended nutritional intervention in older Australian hospitalized patients: a randomized controlled trial.
Sharma Y, Thompson C, Miller M, Shahi R, Hakendorf P, Horwood C, Kaambwa B. Sharma Y, et al. BMC Geriatr. 2018 Feb 5;18(1):41. doi: 10.1186/s12877-018-0736-0. BMC Geriatr. 2018. PMID: 29402228 Free PMC article. Clinical Trial.
Comparative effectiveness research: an empirical study of trials registered in ClinicalTrials.gov.
Bourgeois FT, Murthy S, Mandl KD. Bourgeois FT, et al. PLoS One. 2012;7(1):e28820. doi: 10.1371/journal.pone.0028820. Epub 2012 Jan 9. PLoS One. 2012. PMID: 22253698 Free PMC article.
Cost-Effectiveness Thresholds: the Past, the Present and the Future.
Thokala P, Ochalek J, Leech AA, Tong T. Thokala P, et al. Pharmacoeconomics. 2018 May;36(5):509-522. doi: 10.1007/s40273-017-0606-1. Pharmacoeconomics. 2018. PMID: 29427072 Review.
The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes.
Menon K, de Courten B, Magliano DJ, Ademi Z, Liew D, Zomer E. Menon K, et al. Nutrients. 2022 Jan 4;14(1):215. doi: 10.3390/nu14010215. Nutrients. 2022. PMID: 35011089 Free PMC article.
Measuring health-related quality of life in drug clinical trials: is it given due importance?
Miguel RS, López-González AM, Sanchez-Iriso E, Mar J, Cabasés JM. Miguel RS, et al. Pharm World Sci. 2008 Apr;30(2):154-60. doi: 10.1007/s11096-007-9152-9. Epub 2007 Aug 25. Pharm World Sci. 2008. PMID: 17721699

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems